The second trial provides men with metastatic prostate cancer access to prostate-specific membrane antigen (PSMA)-targeted therapy prior to chemotherapy. Currently, PSMA-targeted therapy is only available after chemotherapy. However, phase III clinical trials have shown that PSMA-targeted therapies are more effective and have lower toxicities than chemotherapies for prostate cancer.
"The 177Lu-PNT2002 Expanded Access Protocol provides PSMA-targeted therapy earlier in the course of disease," said Dr. Ulaner. "We aim to enhance treatment options for patients with metastatic prostate cancer, while avoiding the side effects of chemotherapy.
'Substandard' Control Arms in Clinical Trials– Practice found common in prostate cancer studies
Lutetium LU-177 Trial Acceptance at Duke
New radiopharmaceutical (Ac-225-PSMA-617) has high rates of remission in early trials
Chemo/Pluvicto or Clinical Trial?
Treatment naïve and clinical trials
